Indeed, ABT-199, which does not target BCL-XL, does not lead to platelet loss, and is now FDA approved for treatment of various hematological malignancies and was awarded ‘breakthrough designation’ by the FDA in 2017 [11,61]. The gene discussed is BCL2L1; the disease is hematologic disorder.